These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 19721250)

  • 1. Design of nateglinide controlled release tablet containing erosion matrix tablet and multiple administration study in normal beagle dogs.
    Makino C; Sakai H; Okano A; Yabuki A
    Chem Pharm Bull (Tokyo); 2009 Sep; 57(9):907-13. PubMed ID: 19721250
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nateglinide controlled release tablet containing compressionable enteric coated granules.
    Makino C; Sakai H; Yabuki A
    Chem Pharm Bull (Tokyo); 2010 Sep; 58(9):1136-41. PubMed ID: 20823590
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of decrease in both postprandial blood glucose (PBG) and fasting blood glucose (FBG) levels in normal beagle dogs with nateglinide enteric coated granules and immediate release tablets.
    Makino C; Ninomiya N; Sakai H; Orita H; Okano A; Yabuki A
    Chem Pharm Bull (Tokyo); 2006 Apr; 54(4):409-14. PubMed ID: 16595936
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of food on the oral bioavailability and the pharmacodynamic actions of the insulinotropic agent nateglinide in healthy subjects.
    Karara AH; Dunning BE; McLeod JF
    J Clin Pharmacol; 1999 Feb; 39(2):172-9. PubMed ID: 11563410
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced dissolution and bioavailability of Nateglinide by microenvironmental pH-regulated ternary solid dispersion: in-vitro and in-vivo evaluation.
    Wairkar S; Gaud R; Jadhav N
    J Pharm Pharmacol; 2017 Sep; 69(9):1099-1109. PubMed ID: 28590055
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mealtime glucose regulation with nateglinide in healthy volunteers: comparison with repaglinide and placebo.
    Kalbag JB; Walter YH; Nedelman JR; McLeod JF
    Diabetes Care; 2001 Jan; 24(1):73-7. PubMed ID: 11194245
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of the SLCO1B1*1B haplotype on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide.
    Kalliokoski A; Backman JT; Neuvonen PJ; Niemi M
    Pharmacogenet Genomics; 2008 Nov; 18(11):937-42. PubMed ID: 18854776
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the rapidity of onset of the therapeutic effect between nateglinide and mitiglinide by PK/PD analysis in rats.
    Takanohashi T; Arisaka H; Ubukata K; Hayashi M; Yamada Y
    Eur J Drug Metab Pharmacokinet; 2012 Mar; 37(1):9-15. PubMed ID: 22012638
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of insulinotrophic actions of nateglinide with glibenclamide dissociated from absorption in conscious dogs.
    Okamoto M; Ogihara N; Kawamura W; Ebihara S; Takiguchi K; Morita T; Uchida R; Yamaguchi J; Sakai T; Okuda Y; Hayashi Y; Arakawa Y; Kikuchi M
    Metabolism; 2002 May; 51(5):575-81. PubMed ID: 11979388
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug-drug and food-drug pharmacokinetic interactions with new insulinotropic agents repaglinide and nateglinide.
    Scheen AJ
    Clin Pharmacokinet; 2007; 46(2):93-108. PubMed ID: 17253883
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of nateglinide and its metabolites in subjects with type 2 diabetes mellitus and renal failure.
    Inoue T; Shibahara N; Miyagawa K; Itahana R; Izumi M; Nakanishi T; Takamitsu Y
    Clin Nephrol; 2003 Aug; 60(2):90-5. PubMed ID: 12940610
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of CYP2C9 and SLCO1B1 polymorphisms on the pharmacokinetics and pharmacodynamics of nateglinide in healthy Chinese male volunteers.
    Cheng Y; Wang G; Zhang W; Fan L; Chen Y; Zhou HH
    Eur J Clin Pharmacol; 2013 Mar; 69(3):407-13. PubMed ID: 22842957
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting postprandial hyperglycemia: a comparative study of insulinotropic agents in type 2 diabetes.
    Carroll MF; Gutierrez A; Castro M; Tsewang D; Schade DS
    J Clin Endocrinol Metab; 2003 Nov; 88(11):5248-54. PubMed ID: 14602757
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of timing of administration and meal composition on the pharmacokinetic and pharmacodynamic characteristics of the short-acting oral hypoglycemic agent nateglinide in healthy subjects.
    Luzio SD; Anderson DM; Owens DR
    J Clin Endocrinol Metab; 2001 Oct; 86(10):4874-80. PubMed ID: 11600556
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of nateglinide taken with food on gastric emptying rates in healthy subjects.
    Anderson D; Shelley S; Kellett N; Marshall D; Nimmo W
    Clin Ther; 2003 Jun; 25(6):1722-38. PubMed ID: 12860494
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nateglinide versus repaglinide for type 2 diabetes mellitus in China.
    Li C; Xia J; Zhang G; Wang S; Wang L
    Acta Diabetol; 2009 Dec; 46(4):325-33. PubMed ID: 19183841
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Coadministration of gemfibrozil and itraconazole has only a minor effect on the pharmacokinetics of the CYP2C9 and CYP3A4 substrate nateglinide.
    Niemi M; Backman JT; Juntti-Patinen L; Neuvonen M; Neuvonen PJ
    Br J Clin Pharmacol; 2005 Aug; 60(2):208-17. PubMed ID: 16042675
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacologic restoration of the early insulin response in pre-diabetic monkeys controls mealtime glucose excursions without peripheral hyperinsulinaemia.
    Dunning BE; Deacon R; Gutierrez C; Paladini S; Valentin MA; Foley JE
    Diabetologia; 2003 Mar; 46 Suppl 1():M22-9. PubMed ID: 12652355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Three-Pulse Release Tablet for Amoxicillin: Preparation, Pharmacokinetic Study and Physiologically Based Pharmacokinetic Modeling.
    Li J; Chai H; Li Y; Chai X; Zhao Y; Zhao Y; Tao T; Xiang X
    PLoS One; 2016; 11(8):e0160260. PubMed ID: 27479702
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Comparison of efficacy between nateglinide and repaglinide in treating type 2 diabetes: a randomized controlled double-blind clinical trial].
    Li JW; Tian HM; Yu HL; Zhang XX; Zhao GZ; Wang JN
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2005 Mar; 36(2):267-70. PubMed ID: 15807285
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.